Clinical Trials Browser

Phase 2 × Central Nervous System Diseases × 90 days × Clear all

NCT07326566 2026-06-15

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Phase 2 Recruiting

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma